Gap 27
(Synonyms: Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile ) 目录号 : GP10119
Gap 27是一种由连接蛋白43（Connexin43, Cx43）衍生而来的肽（Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile），是一种选择性间隙连接阻断剂。
Cas No.:198284-64-9
Sample solution is provided at 25 µL, 10mM.
Gap 27 is a peptide (Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile) derived from connexin43 (Cx43) and is a selective gap junction blocker[1, 2]. Gap 27 specifically acts on this protein by mimicking a part of the Cx43 structure, thereby inhibiting intercellular communication mediated by Cx43[3]. Gap junctions are channel structures on adjacent cell membranes that allow small molecules to be directly transferred between cells and are essential for coordinating cell group activities[4].
In vitro, Gap 27 (500µM) treatment of rat osteoclasts cultured on bovine bone slices for 48h significantly reduced the survival rate of osteoclasts and the number of TRAP-positive mononuclear and multinuclear rat osteoclasts[5]. Gap 27 (0.1mM) treatment of primary human corneal epithelial cells (HCEC) enhanced wound closure of HCEC in vitro[6].
In vivo, Gap 27 (1µg/kg) treated with osmotic micropumps for 4 weeks in rats with an arteriovenous fistula model (AV-Shunt) significantly slowed the progression of cardiac function deterioration and significantly improved cardiac function in rats[7].
References:
[1] De Vuyst E, Boengler K, Antoons G, et al. Pharmacological modulation of connexin‐formed channels in cardiac pathophysiology[J]. British journal of pharmacology, 2011, 163(3): 469-483.
[2] Sathiyanadan K, Alonso F, Domingos-Pereira S, et al. Targeting endothelial Connexin37 reduces angiogenesis and decreases tumor growth[J]. International journal of molecular sciences, 2022, 23(6): 2930.
[3] Ribeiro-Rodrigues T M, Martins-Marques T, Morel S, et al. Role of connexin 43 in different forms of intercellular communication–gap junctions, extracellular vesicles and tunnelling nanotubes[J]. Journal of cell science, 2017, 130(21): 3619-3630.
[4] Maeda S, Tsukihara T. Structure of the gap junction channel and its implications for its biological functions[J]. Cellular and Molecular Life Sciences, 2011, 68(7): 1115-1129.
[5] Ilvesaro J, Tavi P, Tuukkanen J. Connexin-mimetic peptide Gap 27 decreases osteoclastic activity[J]. BMC musculoskeletal disorders, 2001, 2(1): 10.
[6] Elbadawy H M, Mirabelli P, Xeroudaki M, et al. Effect of connexin 43 inhibition by the mimetic peptide Gap27 on corneal wound healing, inflammation and neovascularization[J]. British journal of pharmacology, 2016, 173(19): 2880-2893.
[7] Lucero C M, Andrade D C, Toledo C, et al. Cardiac remodeling and arrhythmogenesis are ameliorated by administration of Cx43 mimetic peptide Gap27 in heart failure rats[J]. Scientific Reports, 2020, 10(1): 6878.
Gap 27是一种由连接蛋白43（Connexin43, Cx43）衍生而来的肽（Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile），是一种选择性间隙连接阻断剂[1, 2]。Gap 27通过模拟Cx43的一部分结构，特异性作用于该蛋白，从而抑制由Cx43介导的细胞间通讯[3]。间隙连接是相邻细胞膜上的通道结构，允许小分子物质在细胞间直接传递，对于协调细胞群体活动至关重要[4]。
在体外，Gap 27（500µM）处理培养在牛骨切片上的大鼠破骨细胞48h，显著降低了破骨细胞的存活率，减少了TRAP阳性单核和多核大鼠破骨细胞的数量[5]。Gap 27（0.1mM）处理原代人角膜上皮细胞（HCEC），增强了体外HCEC的伤口闭合[6]。
在体内，Gap 27（1µg/kg）通过渗透性微泵处理动静脉瘘模型（AV-Shunt）大鼠4周，显著减缓了大鼠心脏功能恶化的进展，显著改善了心脏功能[7]。
| Cell experiment [1]: | |
Cell lines | Osteoclasts |
Preparation Method | Mechanically harvested osteoclasts from the long bones of 1 or 2-day-old Sprague-Dawley rat pups were allowed to attach to sonicated bovine cortical bone slices (0.5cm2). After 30min, the non-attached cells were rinsed away, and the remaining cells on the bone slices were cultured in three groups: control, heptanol and Gap 27. The control group was cultured in DMEM (Dulbecco's modified Eagle's medium) buffered with 20mM Hepes and containing 0.84g of sodium bicarbonate/liter, 2mM L-glutamine, 100 IU of penicillin/ml, 100µg of streptomycin/ml and 7% heatinactivated fetal calf serum (FCS), which medium will be later referred to as DMEM-FCS. The heptanol group was cultured in medium with 0.15% ethanol and 3mM heptanol in DMEM-FCS. Third group of bone cells, Gap 27 peptide group, was cultured with Gap 27 peptide at concentration 500µM in DMEM-FCS. In all the three groups cells were cultured for 48h, after which the cultures were stopped by fixing the cells and bone slices with freshly made or refrigerated 3% paraformaldehyde (PFA) and 2% sucrose in PBS for 10min at room temperature. The cells were stained for tartrate-resistant acid phosphatase (TRAP), a commonly accepted marker of osteoclasts, using a TRAP kit according to the manufacturer's instruction. |
Reaction Conditions | 500µM; 48h |
Applications | Gap 27 caused a remarked decrease in the number of both TRAP-positive mononuclear and multinucleated rat osteoclasts cultured on bovine bone slices. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Highoutput heart failure was induced by volume overload using the arterio-venous fistula model (AV-Shunt) in adult male rats. Four weeks after AV-Shunt surgery, the Cx43 mimetic peptide Gap 27 (1µg/kg) or scrambled peptide, were administered via osmotic minipumps (AV-ShuntGap 27 or AV-ShuntScr) for 4 weeks. Cardiac volumes, arrhythmias, function and remodeling were determined at 8 weeks after AV-Shunt surgeries. |
Dosage form | 1µg/kg; 4 week; osmotic minipumps |
Applications | Gap 27 treatment significantly slowed the progression of cardiac deterioration in rats, and intraventricular pressure-volume loop measurements showed a significant improvement in cardiac function. |
References: | |
| Cas No. | 198284-64-9 | SDF | |
| 别名 | Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile | ||
| 化学名 | Gap 27 | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(C(C)CC)C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)O)NC(=O)C2CCCN2C(=O)C(CCCN=C(N)N)NC(=O)C(CO)N | ||
| 分子式 | C60H101N15O17 | 分子量 | 1304.55 |
| 溶解度 | ≥ 65.25mg/mL in DMSO, ≥ 5mg/mL in Water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 766.5 μL | 3.8327 mL | 7.6655 mL |
| 5 mM | 153.3 μL | 766.5 μL | 1.5331 mL |
| 10 mM | 76.7 μL | 383.3 μL | 766.5 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet